YHB Investment Advisors Inc. Sells 26,688 Shares of Edwards Lifesciences Co. (NYSE:EW)

YHB Investment Advisors Inc. lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 76.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,309 shares of the medical research company's stock after selling 26,688 shares during the quarter. YHB Investment Advisors Inc.'s holdings in Edwards Lifesciences were worth $634,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of EW. Castleview Partners LLC bought a new position in Edwards Lifesciences during the first quarter worth about $25,000. Compass Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $31,000. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $34,000. Jackson Grant Investment Advisers Inc. bought a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $38,000. Finally, Janiczek Wealth Management LLC grew its position in Edwards Lifesciences by 108.6% during the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company's stock worth $40,000 after buying an additional 303 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 11,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total transaction of $944,130.00. Following the completion of the transaction, the vice president now owns 39,503 shares of the company's stock, valued at $3,390,542.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the completion of the sale, the vice president now directly owns 39,503 shares in the company, valued at $3,390,542.49. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 over the last ninety days. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Trading Down 1.2 %

EW traded down $1.13 during trading on Friday, reaching $90.28. 3,155,519 shares of the company's stock were exchanged, compared to its average volume of 3,074,077. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The firm has a fifty day moving average price of $90.01 and a two-hundred day moving average price of $77.74. The stock has a market capitalization of $54.34 billion, a PE ratio of 39.25, a price-to-earnings-growth ratio of 4.53 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting the consensus estimate of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. Edwards Lifesciences's revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.64 earnings per share. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on EW shares. Citigroup increased their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a "neutral" rating in a report on Wednesday, April 3rd. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an "overweight" rating in a report on Thursday, March 21st. StockNews.com downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Wednesday, March 20th. Royal Bank of Canada lifted their price objective on shares of Edwards Lifesciences from $82.00 to $95.00 and gave the company an "outperform" rating in a research note on Wednesday, February 7th. Finally, Bank of America upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating in a research note on Thursday, March 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $91.33.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.